NBP
NASDAQNovaBridge Biosciences
Price$1.75+0.08 (+4.49%)
01:30 PM07:45 PM
News · 26 weeks550%
2025-12-072026-05-31
Mix3390d
- Insider22(67%)
- SEC Filings4(12%)
- Other4(12%)
- Leadership2(6%)
- Earnings1(3%)
Latest news
25 items- INSIDERSVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $13,766 worth of Ordinary Shares (3,494 units at $3.94), increasing direct ownership by 2% to 290,154 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- PRNovaBridge to Present at the 2026 Jefferies Global Healthcare ConferenceROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company's senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026. Conference details are as follows: 2026 Jefferies Global Healthcare ConferenceFormat: Company Presentation and one-on-one investor meetingsDate: Thursday, June 4, 2026Presentation time: 3:10 PM ET Webcast Link: Here The webcast of the Jefferies presentation will be accessible on th
- INSIDEROfficer Cao Sean Wuxiong sold $42,584 worth of Ordinary Shares (21,399 units at $1.99), decreasing direct ownership by 38% to 35,073 units (SEC Form 4) to cover taxes4 - NovaBridge Biosciences (0001778016) (Issuer)
- PRNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of NovaBridge's management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference being held on May 19, 2026. Conference details are as follows: H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat Date: Tuesday, May 19, 2026Time: 3:30 PM ETWebcast Link: Here The webcast of the company presentation will be accessible on the News & Events page of th
- INSIDEROfficer Hagler Mark Arnold bought $577,300 worth of Ordinary Shares (230,000 units at $2.51) (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hagler Mark Arnold3 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueSeasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmologyStrengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific antibody for first line (1L) gastric cancer, toward registrational pivotal studies and continues to advance VIS-101, purpose-designed, potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- NovaBridge Bioscienc
- INSIDERAmendment: SEC Form 3 filed by new insider Xu Cong Claire3/A - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 20-F filed by NovaBridge Biosciences20-F - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Reports Full Year 2025 Financial Results and Provides Business UpdateSuccessful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA's Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026VIS-101, a potential best-in-class VEGF-A X ANG-2 inhibitor for wet-AMD, produced rapid, robust and durable responses in treatment naïve wet-AMD patients, and is poi
- INSIDERSEC Form 3 filed by new insider Yang Conor Chia-Hung3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chu Denny Hsueh Wen3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dennis Phillip Andrew3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lin Liwei Lorraine3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fu Xi-Yong3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zhang Xiaofan Neo3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lei Ming Kyler3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wu Joanna Xuqiong3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fu Wei3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cao Sean Wuxiong3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cunningham Emmett3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Xu Cong Claire3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Liu Xin3 - NovaBridge Biosciences (0001778016) (Issuer)
NBP FAQ
6 questionsWhere does NBP stock trade?
NovaBridge Biosciences (NBP) is listed on NASDAQ.What sector and industry is NBP in?
NovaBridge Biosciences operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NovaBridge Biosciences go public?
NovaBridge Biosciences (NBP) completed its IPO in 2020.What are analysts saying about NBP?
NovaBridge Biosciences has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-02-06. Recent price targets cluster around $900.00.What companies are similar to NBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NBP side-by-side with any of them on Quantisnow.How can I track NBP on Quantisnow?
Quantisnow aggregates NovaBridge Biosciences's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBP to receive live email and push alerts on every new disclosure.